

# Effects of Interferon- $\gamma$ 1b on Biomarker Expression in Patients with Idiopathic Pulmonary Fibrosis

Robert M. Strieter, Karen M. Starko, Richard I. Enelow, Imre Noth, Vincent G. Valentine, and the other members of the Idiopathic Pulmonary Fibrosis Biomarkers Study Group

David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles; InterMune, Inc., Brisbane, California; University of Virginia Medical Center, Charlottesville, Virginia; University of Chicago, Chicago, Illinois; Ochsner Clinic Foundation, New Orleans, Louisiana

In a recent study of IFN- $\gamma$  1b in 330 patients with idiopathic pulmonary fibrosis (IPF), progression-free survival was unchanged; however, a trend toward lower mortality was seen in IFN- $\gamma$  1b-treated patients compared with placebo-treated patients (9.9 vs. 16.7%;  $p = 0.08$ ). The purpose of this randomized, double-blind, placebo-controlled trial was to characterize molecular effects of subcutaneous IFN- $\gamma$  1b (200  $\mu$ g) thrice weekly for 6 months versus placebo in 32 patients with IPF. Messenger RNA in transbronchial lung biopsies and bronchoalveolar lavage cell pellet and protein levels in bronchoalveolar lavage fluid (BALF) and plasma were evaluated. After IFN- $\gamma$  1b treatment, IFN-inducible T cell- $\alpha$  chemoattractant/CXCL11 (a chemokine with immunomodulatory, antiangiogenic, and defensin-like antimicrobial properties) increased in BALF ( $p = 0.016$ ) and plasma ( $p < 0.001$ ); BALF levels of epithelial neutrophil-activating protein-78/CXCL5 ( $p = 0.054$ ), platelet-derived growth factor A ( $p = 0.033$ ), and Type I procollagen ( $p = 0.096$ ) were lower; and IFN- $\gamma$  levels were higher ( $p = 0.093$ ) versus placebo. For messenger RNA in transbronchial biopsies, trends ( $p > 0.05$  and  $\leq 0.10$ ) associated with IFN- $\gamma$  1b treatment included an increase in IFN-inducible T cell- $\alpha$  chemoattractant/CXCL11, a decrease in elastin, and smaller increases for Type III procollagen and platelet-derived growth factor B. Changes in biomarkers of fibrosis, angiogenesis, proliferation, immunomodulation, and antimicrobial activity suggest that IFN- $\gamma$  1b may affect IPF through multiple pathways.

**Keywords:** IFN- $\gamma$  1b; proteins; pulmonary fibrosis; RNA

IFN- $\gamma$  1b, a pleiotropic cytokine highly homologous with natural IFN- $\gamma$ , has antimicrobial, antifibrotic, antiproliferative, and im-

munomodulatory properties and has been shown to decrease the frequency and severity of infection in patients with chronic granulomatous disease (1) and to delay the progression of malignant osteopetrosis (2).

In a recent randomized, double-blind, placebo-controlled study of 330 patients with idiopathic pulmonary fibrosis (IPF), IFN- $\gamma$  1b had no effect on the primary endpoint of progression-free survival; however, there was a trend toward decreased mortality in patients treated with IFN- $\gamma$  1b (9.9 vs. 16.7%;  $p = 0.08$ ) with a 41% relative reduction in the risk of death (hazard ratio = 0.6; 95% confidence interval = 0.3–1.1) (3). The mechanism by which survival may be prolonged is not clear.

IPF is characterized by insidious onset of dyspnea and abnormal pulmonary function (4, 5) and a median survival of only 2.5–3.5 years after diagnosis (6). The etiology is unknown, and no therapy has been proved to be beneficial. Histopathologic examination reveals temporal heterogeneity of alternating zones of interstitial fibrosis with fibroblastic foci (i.e., newer fibrosis), inflammation, honeycomb changes (i.e., older fibrosis), and normal lung architecture (4–7). Abnormal levels of angiogenic and angiostatic chemokines (8) and aberrant vascular remodeling are found in conjunction with the fibrotic process (9, 10). A possible pathogenic role for pulmonary infection related to viruses and atypical bacteria has been suggested (5, 11).

Molecular, cellular, and whole-animal studies have identified pathways involved in fibrosis and the production and deposition in the lung of extracellular matrix proteins (e.g., procollagens and elastin). These pathways include growth factors, such as transforming growth factor- $\beta$  (TGF- $\beta$ ), connective tissue growth factor (CTGF), platelet-derived growth factors (PDGF), and cytokines and chemokines associated with inflammation, cellular trafficking, angiogenesis, and immunity (12, 13).

In preclinical studies, IFN- $\gamma$  affects molecules associated with fibrosis and infection or their effects in the following ways: (1) downregulation of extracellular matrix proteins, (14–16) TGF- $\beta$  (17), PDGF (18), epithelial neutrophil-activating protein (ENA-78/CXCL5) (19), interleukin (IL)-8 (IL-8/CXCL8) (19), IL-4 (20), and IL-13 (20); and (2) upregulation of defensins (21) and IFN-inducible CXC chemokines (monokine induced by IFN- $\gamma$  [MIG/CXCL9] [22], IP-10[IFN- $\gamma$ -inducible protein-10]/CXCL10 [22], and IFN-inducible T cell- $\alpha$  chemoattractant [ITAC/CXCL-11] [22, 23]).

We designed this randomized, double-blind, placebo-controlled, multicenter study to characterize the effects of IFN- $\gamma$  1b on biologic markers associated with fibrosis, aberrant vascular remodeling, and immunomodulatory and antimicrobial activity in the lungs and plasma of humans with IPF.

## METHODS

### Patients and Study Design

After giving written informed consent, 32 patients were enrolled at 15 centers in the United States and randomly assigned (1:1) to receive either 200  $\mu$ g (100  $\mu$ g for the first 2 weeks) subcutaneous IFN- $\gamma$  1b ( $n = 17$ )

(Received in original form December 8, 2003; accepted in final form March 23, 2004)

Supported by InterMune, Inc. and the U.S. National Institutes of Health (NIH P50 HL67665). K.B., A.C., A.F., M.K.G., M.P.K., L.L., P.N., I.N., S.S., and D.A.Z. have received honoraria or served as consultants to InterMune. W.B. and K.M.S. are InterMune employees.

The other members of the Idiopathic Pulmonary Fibrosis Biomarkers Study Group are: K. Brown (National Jewish Medical Research Center, Denver, CO), A. Frost (Baylor College of Medicine, Houston, TX), L. Lancaster (Vanderbilt University, Nashville, TN), P. Noble (Yale University School of Medicine, New Haven, CT), A. Chan (University of California, Davis, Sacramento, CA), M. K. Glassberg (University of Miami School of Medicine, Miami, FL), M. Kallay (Highland Hospital, Rochester, NY), P. Economou (Lovelace Scientific Resources, Albuquerque, NM), S. Sahn (Medical University of South Carolina, Charleston, SC), M. Wencil (Wichita Clinic, Wichita, KS), D. A. Zisman (University of Pennsylvania Health System, Philadelphia, PA), W. Bradford (InterMune, Inc., Brisbane, CA), M. Burdick (David Geffen School of Medicine at UCLA, Los Angeles, CA), M. P. Keane (David Geffen School of Medicine at UCLA, Los Angeles, CA), and T. Ganz (David Geffen School of Medicine at UCLA, Los Angeles, CA).

Correspondence and requests for reprints should be addressed to Robert M. Strieter, M.D., 900 Veteran Avenue, 14-154 Warren Hall, P.O. Box 711922, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024-1922. E-mail: rstrieter@mednet.ucla.edu

This article has an online supplement, which is accessible from this issue's table of contents online at [www.atsjournals.org](http://www.atsjournals.org)

Am J Respir Crit Care Med Vol 170, pp 133–140, 2004

Originally Published in Press as DOI: 10.1164/rccm.200312-16700C on March 24, 2004

Internet address: [www.atsjournals.org](http://www.atsjournals.org)

or matching placebo ( $n = 15$ ) thrice weekly for 26 weeks. The principles of the Declaration of Helsinki as endorsed by the U.S. Food and Drug Administration were observed. Patients, age 20 through 79 years, were required to have an FVC of between 50% and less than 90% predicted, confirmation by high-resolution computed tomography and tissue diagnosis, and to be worsening. Patients were required to show lack of improvement after steroids and had to be able and willing to take prednisone 10 mg for at least 21 days before the first bronchoscopy and until the end of study treatment. A complete list of patient inclusion criteria is presented in the online supplement.

Bronchoalveolar lavage (BAL) and transbronchial biopsy (TBB) were performed at baseline and at 6 months (weeks 23–24) to determine messenger RNA (mRNA) transcription in TBB tissue (3 biopsies each from the right, middle, and lower lobes) and BAL cell pellet, as well as protein levels in BAL fluid (BALF) and plasma. Sample collection and initial processing techniques for all centers were standardized by training of site personnel and providing them written instructions for sample preparation, handling, and shipping to the central laboratory at the University of California at Los Angeles. The central laboratory followed standardized procedures for final processing and analysis of all specimens. Prospectively defined biologic markers of growth, fibrosis, angiogenesis, angiostasis, and antimicrobial activity anticipated to be responsive to IFN- $\gamma$  1b (see tables) were assessed in TBB tissue, BAL cell pellet, BALF, and plasma. Expression of mRNA was measured by TaqMan quantitative real-time polymerase chain reaction (PCR) using the ABI Prism Analyzer (Applied Biosystems, Foster City, CA). Proteins, except the defensins, which were measured by bioassay, were measured by specific ELISA; detail is provided in the online supplement. Other endpoints including FVC % predicted, resting arterial blood gas assessment (room air) of alveolar–arterial oxygen gradient, percent predicted diffusion of carbon monoxide, dyspnea, highest oxygen use, and the maximal oxygen flow rate during each month were measured at baseline and at 6 months, in the week before the second bronchoscopy (week 22–23), and at intervening visits (i.e., at weeks 2, 4, 8, 12, 16, and 20). Distance walked in the 6-minute walk test was an exploratory endpoint. Safety was assessed by adverse event monitoring and clinical laboratory tests (hematology, chemistry, liver function, thyroid function, and urinalysis).

### Statistical Analysis

All patients who received at least 80% of the scheduled study drug doses were included in the endpoint analyses. The primary endpoint was the change from baseline to 6 months in the level of mRNA transcription for TGF- $\beta$  and CTGF in TBB tissue (Table 1), adjusted by a stable, constitutively expressed gene, the housekeeping gene GAPDH. Samples that did not contain adequate levels of the housekeeping gene were excluded from the mRNA analyses. Change from baseline was represented by relative expression (RE) calculations as follows:  $RE = 2^{(\Delta Ct_{[pre]} - \Delta Ct_{[post]})}$ , where  $\Delta Ct = FAM - VIC$ . FAM represents the threshold cycle at which the target gene was detected and VIC represents the threshold cycle at which the housekeeping gene was detected. RE is expressed in reference to the baseline amount: a value of RE greater than 1 indicates that more of the target gene was expressed after treatment than before treatment; a value of RE less than 1 indicates that less of the target gene was expressed after treatment than before treatment; and an RE value of 1 indicates no change from baseline. The sample size of 15 patients per group provided more than 90% power to detect a difference of three levels of mRNA transcription for TGF- $\beta$  and CTGF, adjusted for the housekeeping gene and represented by relative expression calculations, between the IFN- $\gamma$  and the placebo groups, assuming a standard deviation of 1.5 levels.

Details of the statistical analysis are provided in the online supplement.

### RESULTS

The first patient enrolled began treatment in January 2002 and the last finished the double-blinded treatment period in October 2002. The majority of patients were male (70.6% in the IFN- $\gamma$  1b group and 53.3% in the placebo group) and white (94.1 and 86.7% in the IFN- $\gamma$  1b the placebo groups, respectively). Mean age was 64.1 years (range, 51–78 years) and 63.0 years (range, 52–75 years) in the respective groups. Clinical and pulmonary

function parameters were similar across the groups at the time of study entry except for longer distance walked in the 6-minute walk test in the IFN- $\gamma$  1b group (mean 423.1 m vs. 340.0 m,  $p = 0.035$ ,  $t$  test) (Table 2). All patients received more than 80% of scheduled doses and were included in all analyses. Of 32 patients enrolled (17 IFN- $\gamma$  1b, 15 placebo), 2 (both placebo recipients) discontinued treatment prematurely for reasons unrelated to the study drug (fatal pneumonia, non-small cell carcinoma). IFN- $\gamma$  1b and placebo recipients took a mean 98.45% (SD,  $\pm 2.020$ ) and 98.09% (SD,  $\pm 5.209$ ) of planned study medication, respectively. At baseline, mRNA was found in the TBB tissue and BAL cell pellet of at least 80% of patients with adequate housekeeping gene for all biomarkers except IL-4 and IL-13 in TBB tissue (found in 30% and 37%, respectively), IL-4 and IL-13 in BAL cell pellet (found in 13% and 19%, respectively), and elastin in BAL cell pellet (found in 55%).

At 6 months, mRNA RE did not differ significantly between the study groups for all biomarkers measured in TBB tissue, including the primary endpoint markers of TGF- $\beta$  and CTGF, or in BAL cell pellet (Table 1). However, a trend toward a statistically significant difference ( $p > 0.05$  and  $\leq 0.10$ ) was seen in TBB tissue mRNA RE in the expected directions for elastin, ITAC/CXCL11, PDGF-B, and Type III procollagen (Table 1). Elastin mRNA RE decreased in the active treatment group but increased in the placebo group (median 0.680 vs. 1.535,  $p = 0.054$ , by analysis of covariance [ANCOVA]). Lesser increases occurred in the active group than in the placebo group in mRNA RE for PDGF-B (1.100 vs. 1.520,  $p = 0.085$ , ANCOVA) and Type III procollagen (1.530 vs. 1.800,  $p = 0.092$ , ANCOVA). Expression of ITAC/CXCL11 increased in the active group but decreased in the placebo group (median 1.560 vs. 0.610,  $p = 0.063$ , ANCOVA) (Figure 1).

In the categorical analyses of TBB tissue and BAL cell pellet, only two findings, both in TBB tissue, were statistically significant or trending toward significance. There was a significant difference between the treatment groups in the expression of IL-4 level, with more patients (45.5%) having an increase in the placebo group than in the active group (5.9%) ( $p = 0.049$ , Wilcoxon rank-sum test). A trend toward downregulation in SMAD-7 ( $p = 0.084$ , Wilcoxon rank-sum test) was contrary to the expected result: among IFN- $\gamma$  1b recipients, SMAD-7 decreased in 70.6% (12/17) and increased in 29.4% (5/17), whereas among placebo recipients, SMAD-7 decreased in 36.4% (4/11) and increased in 63.6% (7/11).

Examination of protein levels with the Wilcoxon rank-sum test revealed statistically significant differences between the treatment groups in ITAC/CXCL11 in both BALF ( $p = 0.016$ ) and plasma ( $p < 0.001$ ), and in PDGF-A in BALF ( $p = 0.033$ ) (Table 3). In BALF, ITAC/CXCL11 increased from a baseline median of 0 pg/ml to 450 pg/ml at 6 months in the IFN- $\gamma$  1b group, but did not change from the baseline median of 0 pg/ml in the placebo group. In plasma, ITAC/CXCL11 rose from a median 0 pg/ml at baseline to 8,150 pg/ml at 6 months in the active drug group, and again the median did not change from the baseline level of 0 pg/ml in the placebo group. These changes were consistent with the upregulation of ITAC/CXCL11 anticipated in association with IFN- $\gamma$  1b treatment. In addition, levels of ENA-78/CXCL5 ( $p = 0.054$ ) and Type I procollagen ( $p = 0.096$ ) decreased, and levels of IFN- $\gamma$  ( $p = 0.093$ ) increased. These changes were consistent with the changes expected in association with IFN- $\gamma$  1b treatment. All other proteins measured in BALF and plasma did not differ significantly between treatment groups. All levels for IL-4 in BALF and plasma were below the level of assay detection.

**TABLE 1. MEDIAN RELATIVE EXPRESSION OF MESSENGER RNA OF BIOLOGIC MARKERS IN TRANSBRONCHIAL BIOPSY TISSUE AND BROCHOALVEOLAR LAVAGE CELL PELLET FOR CHANGE FROM BASELINE TO THE 6-MONTH ENDPOINT**

| Biomarker             | Transbronchial Biopsy |       |         |       |                      | BAL Cell Pellet  |       |         |       |                      |
|-----------------------|-----------------------|-------|---------|-------|----------------------|------------------|-------|---------|-------|----------------------|
|                       | IFN- $\gamma$ 1b      |       | Placebo |       |                      | IFN- $\gamma$ 1b |       | Placebo |       |                      |
|                       | n                     | RE*   | n       | RE*   | p Value <sup>†</sup> | n                | RE*   | n       | RE*   | p Value <sup>‡</sup> |
| TGF- $\beta$          | 17                    | 1.300 | 9       | 1.420 | 0.811                | 17               | 1.100 | 12      | 1.380 | 0.586                |
| CTGF                  | 17                    | 1.250 | 11      | 0.620 | 0.433                | 17               | 1.040 | 12      | 0.595 | 0.371                |
| Type I procollagen    | 17                    | 0.740 | 11      | 1.790 | 0.754                | 17               | 0.760 | 12      | 0.340 | 0.705                |
| Type III procollagen  | 15                    | 1.530 | 11      | 1.800 | <b>0.092</b>         | 16               | 1.495 | 12      | 3.360 | 0.763                |
| Elastin               | 16                    | 0.680 | 10      | 1.535 | <b>0.054</b>         | 17               | 0.370 | 12      | 2.055 | 1.000                |
| PDGF-A                | 17                    | 0.730 | 11      | 1.000 | 0.109                | 17               | 2.880 | 12      | 0.695 | 0.877                |
| PDGF-B                | 17                    | 1.100 | 11      | 1.520 | <b>0.085</b>         | 17               | 1.510 | 11      | 1.250 | 0.646                |
| PDGF-D                | 17                    | 0.910 | 11      | 0.870 | 0.354                | 17               | 0.900 | 11      | 1.830 | 0.940                |
| IL-8/CXCL8            | 15                    | 0.950 | 11      | 0.600 | 0.343                | 17               | 0.150 | 12      | 0.560 | 0.191                |
| ENA-78/CXCL5          | 17                    | 1.670 | 11      | 1.010 | 0.814                | 17               | 1.030 | 12      | 1.425 | 0.254                |
| IP-10/CXCL10          | 17                    | 1.240 | 11      | 0.820 | 0.903                | 17               | 0.250 | 12      | 0.585 | 0.735                |
| MIG/CXCL9             | 16                    | 1.040 | 11      | 0.970 | 0.522                | 17               | 0.480 | 12      | 0.525 | 0.934                |
| ITAC/CXCL11           | 15                    | 1.560 | 11      | 0.610 | <b>0.063</b>         | 17               | 0.240 | 12      | 0.385 | 0.688                |
| MDC/CCL22             | 17                    | 0.870 | 11      | 1.030 | 0.190                | 17               | 0.950 | 12      | 1.485 | 0.401                |
| MIP-1 $\delta$ /CCL15 | 17                    | 0.640 | 11      | 0.470 | 0.315                | 17               | 0.730 | 12      | 0.990 | 0.881                |
| IL-4                  | 17                    | 2.200 | 11      | 1.870 | 0.202                | 17               | 0.970 | 12      | 4.420 | 0.186                |
| IL-13                 | 17                    | 1.070 | 11      | 0.070 | 0.425                | 17               | 1.930 | 12      | 2.260 | 0.902                |
| IFN- $\gamma$         | 14                    | 0.610 | 10      | 1.670 | 0.164                | 17               | 0.090 | 12      | 0.635 | 0.401                |
| SMAD-7                | 17                    | 0.910 | 11      | 1.410 | 0.218                | 17               | 1.430 | 11      | 1.220 | 0.954                |

*Definition of abbreviations:* BAL = bronchoalveolar lavage; CTGF = connective tissue growth factor; ENA = epithelial neutrophil-activating protein; IL = interleukin; IP-10 = IFN- $\gamma$ -inducible protein-10; ITAC = IFN-inducible T cell- $\alpha$  chemoattractant; MDC = macrophage-derived chemokine; MIG = monokine induced by IFN- $\gamma$ ; MIP-1 $\delta$  = macrophage inflammatory protein-1 $\delta$ ; PDGF = platelet-derived growth factors; RE = relative expression; TGF = transforming growth factor.

The numbers (n) represent those samples with adequate levels of housekeeping gene.

p Values representing trends ( $p \leq 0.1$ ) are shown in bold.

\* RE =  $2^{(\Delta\Delta Ct[pre] - \Delta Ct[post])}$ . A value of RE > 1 indicates that more target gene was expressed after treatment than before; a value of RE < 1 indicates that less target gene was expressed after treatment than before; and an RE value of 1 indicates no change from baseline.

<sup>†</sup> Wilcoxon rank-sum test for ENA-78/CXCL5; analysis of covariance (ANCOVA) applied to  $\log_{10}$ -transformed RE (with classification effect for treatment and baseline  $\log_{10} \Delta Ct[pre]$  as covariate) for other markers.

<sup>‡</sup> Wilcoxon rank-sum test for elastin and IL-8; analysis of variance with classification effect for treatment for CTGF, ENA-78/CXCL5, MDC/CCL22, and TGF- $\beta$ ; ANCOVA (see note above) for other markers.

For the clinical measures, statistical significance was approached in favor of the IFN- $\gamma$  1b group for alveolar-arterial gradient (mean change from baseline of  $-0.3$  vs.  $6.0$  mm Hg,  $p = 0.054$ , ANCOVA) and for FEV<sub>1</sub> in liters (mean change from baseline of  $0.014$  vs.  $-0.128$ ,  $p = 0.067$ , ANCOVA). No other changes from baseline to the 6-month endpoint were statistically significant or showed a trend toward significance for functional tests, dyspnea, oxygen use, or distance walked during the 6-minute walk test, and except for alveolar-arterial gradient and FEV<sub>1</sub>, changes in the functional and pulmonary test results over this 6-month period were clinically minimal (Table 4).

Treatment-emergent adverse events were reported by most patients in both treatment groups (94.1% in the IFN- $\gamma$  1b group and 86.7% in the placebo group). More patients had constitutional symptoms in the IFN- $\gamma$  1b group than in the placebo group, including headache (47.1 vs. 20.0%), pyrexia (35.3 vs. 6.7%), and fatigue (35.3 vs. 13.3%). The number of patients with serious adverse events was lower in the IFN- $\gamma$  1b group (5.9%, 1 event in 1 patient) than in the placebo group (40.0%, 11 events in 6 patients). One placebo patient with pneumonia died.

No clinically significant differences between the treatment groups were seen in changes in total BAL cell count or changes in percentage of alveolar macrophages, lymphocytes, or neutrophils between baseline and 6 months (Table 5). Most treatment-emergent laboratory toxicities were mild or moderate in severity; no laboratory toxicity was cited as a serious adverse event and none required discontinuation of the study treatment.

## DISCUSSION

This is the first study in humans to characterize the effects of IFN- $\gamma$  1b on blood and lung biomarkers, hypothesized to play a central role in the pathogenesis of IPF. Our results are consistent with extensive preclinical data indicating that IFN- $\gamma$  down-regulates molecules associated with fibrosis, proliferation, and inflammation, and upregulates molecules associated with antimicrobial defense and antiangiogenesis (14–24). These findings may provide a basis for the recent results from a large clinical trial in which a trend toward prolonged survival time was observed in patients treated with IFN- $\gamma$  1b (3).

Using the extremely sensitive TaqMan real-time PCR to measure mRNA expression, we found that most of the molecules we examined were expressed before treatment in these IPF patients. Only mRNA for IL-4 and IL-13 in lung tissue and BAL cell pellet and elastin in BAL cell pellet were not detected in most patients.

Based on the report by Ziesche and colleagues (25), the primary hypothesis for this study was that IFN- $\gamma$  1b would down-regulate mRNA for TGF- $\beta$  or CTGF. In contrast to the finding of Ziesche and colleagues (25), we did not detect a direct effect of IFN- $\gamma$  1b on mRNA for TGF- $\beta$  or CTGF. To our knowledge, the Ziesche study is the only study to report an IFN- $\gamma$  1b-mediated downregulation of these molecules in humans. Lack of effect on transcription, however, does not negate preclinical data showing that IFN- $\gamma$  modifies TGF- $\beta$  effects through other pathways. Preclinical studies have provided considerable evidence of the antifibrotic actions of IFN- $\gamma$ , including direct inhibition of

TABLE 2. BASELINE CHARACTERISTICS

| Characteristic               | IFN- $\gamma$ 1b<br>(n = 17) | Placebo<br>(n = 15) | p Value <sup>†</sup> |
|------------------------------|------------------------------|---------------------|----------------------|
| Age, yr                      |                              |                     |                      |
| 51–60                        | 5 (29.4%)                    | 7 (46.7%)           | 0.698                |
| 61–70                        | 7 (41.2%)                    | 5 (33.3%)           | —                    |
| 71–80                        | 5 (29.4%)                    | 3 (20.0%)           | —                    |
| Mean (SD)                    | 64.1 (7.54)                  | 63.0 (8.60)         | —                    |
| Median                       | 64.0                         | 63.0                | —                    |
| Range                        | 51–78                        | 52–75               | —                    |
| Sex                          |                              |                     |                      |
| Male                         | 12 (70.6%)                   | 8 (53.3%)           | 0.467                |
| Female                       | 5 (29.4%)                    | 7 (46.7%)           | —                    |
| Race                         |                              |                     |                      |
| White                        | 16 (94.1%)                   | 13 (86.7%)          | 0.212                |
| Asian                        | 1 (5.9%)                     | 0                   | —                    |
| Hispanic/Latino              | 0                            | 2 (13.3%)           | —                    |
| Days from IPF diagnosis*     |                              |                     |                      |
| Mean (SD)                    | 340.1 (261.02)               | 377.1 (396.01)      | 0.680                |
| Median                       | 310.5                        | 268.0               | —                    |
| Range                        | 97–1135                      | 72–1482             | —                    |
| A-a gradient (mm Hg)         |                              |                     |                      |
| Mean (SD)                    | 19.974 (9.4954)              | 20.814 (9.9562)     | 0.809                |
| Median                       | 17.770                       | 20.520              | —                    |
| Range                        | 5.82–39.90                   | 3.53–41.85          | —                    |
| FVC % predicted              |                              |                     |                      |
| Mean (SD)                    | 67.0 (12.21)                 | 67.6 (12.04)        | 0.890                |
| Median                       | 70.0                         | 67.0                | —                    |
| Range                        | 51–85                        | 51–93               | —                    |
| D <sub>LCO</sub> % predicted |                              |                     |                      |
| Mean (SD)                    | 43.8 (9.16)                  | 40.1 (10.80)        | 0.312                |
| Median                       | 43.0                         | 39.0                | —                    |
| Range                        | 31–61                        | 28–65               | —                    |
| 6-minute walk test, m        |                              |                     |                      |
| Mean (SD)                    | 423.1 (119.70)               | 340.0 (87.99)       | 0.035                |
| Median                       | 437.0                        | 324.0               | —                    |
| Range                        | 227–690                      | 199–511             | —                    |

Definition of abbreviations: A-a = alveolar-arterial; D<sub>LCO</sub> = diffusing capacity of carbon monoxide; IPF = idiopathic pulmonary fibrosis.

All randomized patients, n = 32.

\* n = 14 for IFN- $\gamma$  1b; n = 13 for placebo.

<sup>†</sup> t-Test for continuous data, Wilcoxon rank-sum test for time-to-event variables, and Fisher's exact test for categorical variables.

proliferation of fibroblasts (14); inhibition of collagen synthesis by cultured human lung fibroblasts *in vitro* (14, 15); reversal of stimulation of collagen gene expression by TGF- $\beta$  in normal human fibroblasts (17); and inhibition of signaling, and thereby gene activation, by TGF- $\beta$  (24). In the bleomycin model of pulmonary fibrosis, IFN- $\gamma$  appeared to decrease the number of collagen fibers (16, 26) and significantly decreased both the total hydroxyproline content of the lungs (16, 26) and the number of fibroblasts (26). Thus, downregulation of the fibrotic process by IFN- $\gamma$  1b may occur both directly and indirectly by modification of the fibroblast response to TGF- $\beta$ . It is also possible that lesser degrees of change may occur than were detectable in this study.

In this study, we found statistically significant differences ( $p \leq 0.05$ ) or trends ( $p > 0.05$  and  $\leq 0.10$ ) in changes in biomarkers of fibrosis consistently in the direction expected given the proposed effects of IFN- $\gamma$  1b based on preclinical data. These biomarker results were secondary endpoints, and the p values were not adjusted for multiplicity; thus, these results should be considered as information for generating hypotheses for future research rather than as definitive. For example, we demonstrated downregulation of mRNA for elastin, Type III procollagen, PDGF-B, and, in the categorical analysis, IL-4 and upregulation of mRNA for ITAC/CXCL11 in the lung versus placebo. In addition, we observed increased protein levels of ITAC/CXCL11 in BALF




Figure 1. Relative expression (at 6 months compared with baseline) of CXCL11 messenger RNA in transbronchial biopsy tissue (medians,  $\pm$  25th and 75th percentile).

and plasma and decreased BALF protein levels of ENA-78/CXCL5, Type I procollagen, and PDGF-A. Only the categorical analysis of SMAD-7 mRNA in the lung trended opposite the expected direction, and the biological significance of this trend, if any, is unclear. These molecules are known to be important in fibrosis. Elastin mRNA was elevated 70- to 80-fold in a butylated hydroxytoluene and oxygen model of fibrosis (27). Type III procollagen predominates in early granulation tissue formation and is gradually replaced by Type I procollagen (28). Both PDGF-A and PDGF-B are elevated in alveolar macrophages from patients with IPF, and PDGF-B is increased 10-fold as much as PDGF-A (29). IL-4 promotes fibroblast synthesis of extracellular matrix proteins (30) and is a chemotactic factor for fibroblasts (31). The changes in expression of these molecules (less elastin, Types I and III procollagen, PDGF-A, PDGF-B, ENA-78/CXCL5, and IL-4) after treatment with IFN- $\gamma$  1b, as compared with changes after placebo treatment, suggest beneficial effects of IFN- $\gamma$  1b on the process of fibrosis.

Results of a recently completed Phase III study of 330 patients with IPF randomized to IFN- $\gamma$  1b or placebo for approximately 1 year, however, demonstrated little change on clinical measures of fibrosis (FVC and alveolar-arterial gradient) but did show a potentially large effect on mortality (3). This apparent paradox between a treatment effect on survival and the absence of any effect on conventional measures of disease progression could be explained either by the insensitivity of these functional outcomes to an IFN- $\gamma$  1b effect on fibrosis or by a different mechanism of action. In this study, we also assessed the impact of IFN- $\gamma$  1b on pathogenic mechanisms other than fibrosis, based on favorable preclinical evidence of an effect on host defense and angiogenesis.

Infectious agents have been postulated to play a role in the pathogenesis of IPF (4, 11). The strongest finding in this study was an upregulation of ITAC/CXCL11 mRNA in lung tissue, coupled with a significant increase in protein levels of ITAC/CXCL11 in BALF and plasma. In a recent radial diffusion assay study, ITAC/CXCL11, an IFN-inducible CXC chemokine, and the other CXC chemokines IP-10/CXCL10 and MIG/CXCL9, demonstrated defensin-like antimicrobial activity in potentially microbicidal concentrations against *Escherichia coli* and *Listeria monocytogenes* (21). This finding expands previous observa-

**TABLE 3. BASELINE MEAN (SD), AND MEAN CHANGE (SE) FROM BASELINE TO 6 MONTHS OF BIOLOGIC MARKERS\* EXPRESSED IN BRONCHOALVEOLAR LAVAGE FLUID AND PLASMA<sup>†</sup>**

| Biomarker           | Time Point         | BALF               |                       |                      | Plasma           |                  |                      |
|---------------------|--------------------|--------------------|-----------------------|----------------------|------------------|------------------|----------------------|
|                     |                    | IFN- $\gamma$ 1b   | Placebo               | p Value <sup>‡</sup> | IFN- $\gamma$ 1b | Placebo          | p Value <sup>§</sup> |
| TGF- $\beta$        | Baseline mean (SD) | 0 (0)              | 6 (23)                | —                    | 10,195 (6,345)   | 11,057 (10,399)  | —                    |
|                     | Mean change (SE)   | 0 (0)              | 5 (14)                | 1.000                | 3784 (6,834)     | -755 (4,316)     | 0.834                |
| Type I procollagen  | Baseline mean (SD) | 1,159 (1,192)      | 453 (774)             | —                    | ND               | ND               | —                    |
|                     | Mean change (SE)   | -534 (342)         | 519 (330)             | <b>0.096</b>         | ND               | ND               | ND                   |
| PDGF-A              | Baseline mean (SD) | 88 (177)           | 3 (10)                | —                    | 70 (250)         | 78 (174)         | —                    |
|                     | Mean change (SE)   | -71 (47)           | 51 (35)               | <b>0.033</b>         | -61 (62)         | 25 (97)          | 1.000                |
| PDGF-B              | Baseline mean (SD) | 4 (10)             | 0 (0)                 | —                    | 30 (124)         | 29 (56)          | —                    |
|                     | Mean change (SE)   | -4 (2)             | 3 (3)                 | 0.108                | -14 (35)         | 46 (65)          | 0.735                |
| IL-8/ CXCL8         | Baseline mean (SD) | 26 (107)           | 170 (324)             | —                    | 68 (210)         | 5 (21)           | —                    |
|                     | Mean change (SE)   | 1 (33)             | -16 (40)              | 0.532                | -68 (51)         | -6 (6)           | 0.688                |
| ENA-78/CXCL5        | Baseline mean (SD) | 179 (283)          | 231 (221)             | —                    | 299 (403)        | 267 (378)        | —                    |
|                     | Mean change (SE)   | -98 (72)           | 54 (61)               | <b>0.054</b>         | 60 (113)         | 132 (169)        | 0.785                |
| IP-10/CXCL10        | Baseline mean (SD) | 41 (167)           | 8 (22)                | —                    | 40 (138)         | 69 (172)         | —                    |
|                     | Mean change (SE)   | -41 (41)           | 3 (3)                 | 0.108                | 67 (65)          | -16 (40)         | 0.821                |
| MIG/CXCL9           | Baseline mean (SD) | 279 (1,152)        | 347 (985)             | —                    | 319 (909)        | 87 (276)         | —                    |
|                     | Mean change (SE)   | -279 (279)         | 86 (93)               | 0.322                | 1219 (696)       | 140 (136)        | 0.133                |
| ITAC/CXCL11         | Baseline mean (SD) | 62 (255)           | 0 (0)                 | —                    | 217 (517)        | 563 (1,440)      | —                    |
|                     | Mean change (SE)   | 346 (94)           | 60 (60)               | <b>0.016</b>         | 10813 (1,924)    | -489 (453)       | < <b>0.001</b>       |
| MDC                 | Baseline mean (SD) | 9 (13)             | 105 (342)             | —                    | 1372 (2,281)     | 7,194 (23,757)   | —                    |
|                     | Mean change (SE)   | -1 (4)             | 77 (65)               | 0.115                | 96 (614)         | 503222 (501,417) | 0.315                |
| MIP-1 $\delta$      | Baseline mean (SD) | 114 (170)          | 160 (143)             | —                    | 2629 (1,261)     | 2,691 (774)      | —                    |
|                     | Mean change (SE)   | -7 (32)            | 18 (34)               | 0.475                | -60 (153)        | 79 (174)         | 0.554                |
| IL-4                | Baseline mean (SD) | 0 (0)              | 0 (0)                 | —                    | 0 (0)            | 0 (0)            | —                    |
|                     | Mean change (SE)   | 0 (0)              | 0 (0)                 | N/C                  | 0 (0)            | 0 (0)            | N/C                  |
| IL-13               | Baseline mean (SD) | 4 (9)              | 15 (40)               | —                    | 0 (0)            | 0 (0)            | —                    |
|                     | Mean change (SE)   | 26 (12)            | -12 (13)              | 0.145                | 2 (2)            | 0 (0)            | 0.420                |
| IFN- $\gamma$       | Baseline mean (SD) | 43 (119)           | 52 (199)              | —                    | 0 (0)            | 49 (191)         | —                    |
|                     | Mean change (SE)   | 37 (73)            | 20 (72)               | <b>0.093</b>         | 90 (71)          | 115 (152)        | 0.788                |
| $\beta$ -defensin-2 | Baseline mean (SD) | 6,785 (2,977)      | 7,822 (4,628)         | —                    | ND               | ND               | —                    |
|                     | Mean change (SE)   | -824 (1,029)       | -1232 (2,156)         | 0.706                | ND               | ND               | ND                   |
| Neutrophil defensin | Baseline mean (SD) | 829,531 (796,203)  | 1,855,977 (2,323,848) | —                    | ND               | ND               | —                    |
|                     | Mean change (SE)   | -333,704 (197,974) | -873,078 (700,861)    | 0.738                | ND               | ND               | ND                   |
| VEGF                | Baseline mean (SD) | 15 (42)            | 3 (10)                | —                    | 4 (12)           | 5 (21)           | —                    |
|                     | Mean change (SE)   | -10 (7)            | -3 (3)                | 0.688                | 6 (9)            | -6 (6)           | 0.520                |

*Definition of abbreviations:* BALF = bronchoalveolar lavage fluid; ENA = epithelial neutrophil-activating protein; IL = interleukin; IP-10 = IFN- $\gamma$ -inducible protein-10; ITAC = IFN-inducible T cell- $\alpha$  chemoattractant; MDC = macrophage-derived chemokine; MIG = monokine induced by IFN- $\gamma$ ; MIP-1 $\delta$  = macrophage inflammatory protein-1 $\delta$ ; N/C = not calculable (test cannot be done due to zero variability); ND = not done; PDGF = platelet-derived growth factors; TGF = transforming growth factor; VEGF = vascular endothelial growth factor.

\* Laboratory results were reported in ng/ml and converted to pg/ml for this presentation.

<sup>†</sup> For IFN- $\gamma$  1b group, n = 17 at baseline and Month 6 for all biomarkers; for placebo group, n = 15 at baseline and n = 13 at Month 6 for all biomarkers.

<sup>‡</sup> Wilcoxon rank-sum test. p values representing trends (p  $\leq$  0.1) and significant differences (p  $\leq$  0.05) are highlighted in bold text.

<sup>§</sup> ANCOVA (see <sup>†</sup>, above) for MIP-1 $\delta$ ; Wilcoxon rank-sum test for other markers. P value representing significant difference (p  $\leq$  0.05) is highlighted in bold text.

tions in humans of the antimicrobial actions of IFN- $\gamma$  1b that include increased Fc $\chi$  receptor expression on phagocytes, increased serum levels of opsonin LPS-binding protein, improvement in phagocytes' capacity to ingest microbes, and improvement in phagocyte trafficking (32). These characteristics of IFN- $\gamma$  1b support the clinical observation that IFN- $\gamma$  1b ameliorates infection in both chronic granulomatous disease and malignant osteopetrosis (2). Thus, IFN- $\gamma$  1b could potentially modulate infectious processes that fuel the pathogenesis of IPF or could reduce the incidence or severity of infectious sequelae of IPF.

In addition to its direct antimicrobial activity, ITAC/CXCL11 also inhibits angiogenesis, (22) which could favorably impact the pathogenesis of IPF through several mechanisms, including shunt formation or less aberrant vascular remodeling resulting in diminished fibrosis. Like IP-10/CXCL10 and MIG/CXCL9, ITAC/CXCL11 inhibits neovascularization in the corneal micropocket assay of angiogenesis in response to either of the CXC chemokines, vascular endothelial growth factor, or basic fibroblast growth factor, by ligation to their putative recep-

tor (CXCR3) on endothelial cells (33, 34). We have previously demonstrated that the IFN-inducible CXC chemokine, IP-10/CXCL10, inhibits bleomycin-induced pulmonary fibrosis by suppressing angiogenesis (35), and, in a similar preclinical model, ITAC/CXCL11 treatment analogously inhibits bleomycin-induced pulmonary fibrosis (unpublished observation, R. Strieter, 1 May 2003).

We believe it is unlikely that the ITAC/CXCL11 levels in the BAL simply reflect the levels in plasma due to leakage into the alveolar airspace. The dilutional effect of the volume of BALF used in this study could lead to a 100- to 200-fold decrease in the measured levels of the cytokines. If this dilutional effect is taken into account, the 6-month level of ITAC/CXCL11 (450 pg/ml) measured in the BAL would represent approximately 45–90 ng/ml at the tissue level. These levels are clearly higher than the levels that were measured in the plasma at 6 months (8.15 ng/ml).

Importantly, we found no evidence of a proinflammatory effect of IFN- $\gamma$  1b. Examination of BAL cells revealed stability

TABLE 4. CLINICAL ENDPOINTS AT BASELINE AND 6-MONTH ENDPOINT\*

| Parameter   | IFN- $\gamma$ 1b (n = 17) <sup>†</sup> | Placebo (n = 15) <sup>‡</sup> | p value <sup>§</sup> |
|---|--|-------------------------------|----------------------|
| Secondary Efficacy Endpoints                                |  |                               |                      |
| Mean % predicted FVC  |  |                               |                      |
| Baseline  | 67.0                                   | 67.6                          | —                    |
| 6-Month endpoint  | 65.9                                   | 64.7                          | —                    |
| Mean change (SE)  | -1.0 (1.44)                            | -3.0 (1.54)                   | 0.374                |
| Mean FVC, L   |  |                               |                      |
| Baseline  | 2.669                                  | 2.471                         | —                    |
| 6-Month endpoint  | 2.641                                  | 2.366                         | —                    |
| Mean change (SE)  | -0.036 (0.0519)                        | -0.096 (0.0552)               | 0.435                |
| Mean A-a gradient, mm Hg                                    |  |                               |                      |
| Baseline  | 19.974                                 | 20.814                        | —                    |
| 6-Month endpoint  | 19.699                                 | 26.783                        | —                    |
| Mean change (SE)  | -0.272 (2.1274)                        | 5.965 (2.2650)                | 0.054                |
| Mean % DL <sub>CO</sub>                                     |  |                               |                      |
| Baseline  | 43.8                                   | 40.1                          | —                    |
| 6-Month endpoint  | 40.0                                   | 36.7                          | —                    |
| Mean change (SE)  | -3.4 (1.75)                            | -3.8 (1.87)                   | 0.881                |
| Mean change in modified MRC scale <sup>¶</sup>              |  |                               |                      |
| Baseline to endpoint  | 0.13                                   | 0.29                          | 0.512                |
| Mean dyspnea indices (SD)                                   |  |                               |                      |
| BDI <sup>  </sup>   | 6.4 (1.84)                             | 6.1 (2.26)                    | 0.490                |
| TDI <sup>**</sup>   | 0.2 (2.30)                             | -1.4 (3.59)                   | 0.216                |
| UCSD Shortness of Breath Questionnaire <sup>††</sup>        |  |                               |                      |
| Baseline, Mean (SD)   | 35.3 (17.44)                           | 47.1 (22.42)                  | —                    |
| Baseline to 6-month endpoint, mean change (SE)              | 6.2 (5.21)                             | 8.3 (4.96)                    | 0.573                |
| Most severe O <sub>2</sub> use requirement                  |  |                               |                      |
| At baseline   |  |                               |                      |
| None  | 12 (80%)                               | 11 (78.6%)                    | —                    |
| With activity   | 1 (6.7%)                               | 3 (24.1%)                     | —                    |
| At rest   | 2 (13.3%)                              | 0                             | 0.951                |
| At 6-month endpoint   |  |                               |                      |
| None  | 10 (62.5%)                             | 6 (42.9%)                     | —                    |
| With activity   | 4 (25.0%)                              | 2 (14.3%)                     | —                    |
| At rest   | 2 (12.5%)                              | 6 (42.9%)                     | 0.149                |
| Median weekly maximal flow rate, L/min                      |  |                               |                      |
| At baseline   | 0.00                                   | 0.00                          | 0.866                |
| At 6-month endpoint   | 0.00                                   | 2.00                          | 0.603                |
| Other clinical measures                                     |  |                               |                      |
| Mean % predicted FEV <sub>1</sub>                           |  |                               |                      |
| At baseline   | 72.6                                   | 73.7                          | —                    |
| At 6-month endpoint   | 73.5                                   | 69.7                          | —                    |
| Mean change (SE)  | 0.9 (2.05)                             | -4.0 (2.19)                   | 0.112                |
| Mean % predicted TLC  |  |                               |                      |
| Baseline  | 62.3                                   | 61.8                          | —                    |
| 6-month endpoint  | 63.3                                   | 60.8                          | —                    |
| Mean change (SE)  | 1.0 (1.78)                             | -1.0 (1.99)                   | 0.465                |
| Mean distance walked in 6-minute walk test, m <sup>‡‡</sup> |  |                               |                      |
| Baseline mean   | 423.1                                  | 334.3                         | —                    |
| 6-month endpoint  | 415.9                                  | 329.0                         | —                    |
| Mean change (SE)  | -7.8 (28.18)                           | -4.6 (31.30)                  | 0.942                |

Definition of abbreviations: A-a = alveolar-arterial; BDI = baseline dyspnea index; DL<sub>CO</sub> = diffusing capacity of carbon monoxide; MRC = Medical Research Council; TDI = transition (endpoint) dyspnea index; TLC = total lung capacity; UCSD = University of California at San Diego.

\* Six-month endpoint was the last postbaseline measurement before the second bronchoscopy.

<sup>†</sup> Except for TLC (n = 15), most severe O<sub>2</sub> use requirement (n = 15 at baseline, n = 16 at endpoint), weekly maximal flow rate (n = 16 at baseline, n = 17 at endpoint), and modified MRC scale (n = 16).

<sup>‡</sup> Except for TLC (n = 12), 6-minute walk test (n = 14), transitional dyspnea index (n = 14), most severe O<sub>2</sub> use requirement (n = 14 at baseline and endpoint), weekly maximal flow rate (n = 14 at baseline and endpoint), UCSD Shortness of Breath Questionnaire (n = 14), and modified MRC scale (n = 14).

<sup>§</sup> p Value derived from ANCOVA with classification effect for treatment and baseline value included as a covariate except for Wilcoxon rank-sum comparisons of dyspnea indices, most severe O<sub>2</sub> use requirement, and weekly maximal flow rate.

<sup>¶</sup> Modified MRC scale: 0 = none; 1 = slight; 2 = moderate; 3 = severe; 4 = very severe.

<sup>||</sup> BDI is the sum of assessment in three areas: functional impairment, magnitude of task, and magnitude of effort, each rated on a scale of 0 (very severe) to 4 (no impairment).

<sup>\*\*</sup> TDI is rated on a scale from -3 (major deterioration) to +3 (major improvement) for each of three areas (functional impairment, magnitude of task, and magnitude of effort), which are then summed.

<sup>††</sup> Total scale ranged from 0-120 with higher values indicating increasing shortness of breath.

<sup>‡‡</sup> Exploratory endpoint.

**TABLE 5. MEAN CELL COUNT\* AND PERCENTAGE OF ALVEOLAR MACROPHAGES, LYMPHOCYTES, AND NEUTROPHILS IN BRONCHOALVEOLAR LAVAGE: BASELINE AND CHANGE FROM BASELINE AT 6 MONTHS<sup>†</sup>**

|                                | IFN- $\gamma$ 1b | Placebo |
|--------------------------------|------------------|---------|
| Mean cell count, $\times 1000$ |                  |         |
| Baseline                       | 155              | 247     |
| Change from baseline           | 17               | 22      |
| Alveolar macrophages, %        |                  |         |
| Baseline                       | 70               | 71      |
| Change from baseline           | 16               | 4       |
| Lymphocytes, %                 |                  |         |
| Baseline                       | 11               | 14      |
| Change from baseline           | -5               | -5      |
| Neutrophils, %                 |                  |         |
| Baseline                       | 7                | 12      |
| Change from baseline           | -2               | 1       |

\* Excluding red blood cells.

<sup>†</sup> n = 17 for IFN- $\gamma$  1b and n = 15 for placebo at baseline; n = 17 for IFN- $\gamma$  1b and n = 13 for placebo at 6 months.

of cell counts after 6 months of treatment, suggesting no increase in inflammatory activity in BALF. In addition, ENA-78/CXCL5 in BALF was decreased relative to baseline in patients treated with IFN- $\gamma$  1b. Like IL-8/CXCL8, ENA-78/CXCL5 is a potent chemoattractant and activator of neutrophils (19), as well as a promoter of angiogenesis (36) in IPF (37).

No changes were observed for the remaining molecules (i.e., IL-8/CXCL8, IP-10/CXCL10, MIG/CXCL9, MDC (macrophage-derived chemokine)/CCL22, IL-13, defensins, and vascular endothelial growth factor). Reasons for these observations might include, in addition to true lack of effect, effects of dose, timing of measurements, and sampling.

Significant differences between treatment groups were not observed in pulmonary function, dyspnea, or oxygen use; however, trends toward improvement in alveolar-arterial gradient and FEV<sub>1</sub> were observed. Prolonged treatment with IFN- $\gamma$  1b was well tolerated in patients with steroid-refractory IPF. No IFN- $\gamma$  1b recipient discontinued study drug treatment for any reason, and no deaths occurred in the IFN- $\gamma$  1b treatment group.

This study provides direct evidence in humans with IPF that IFN- $\gamma$  1b alters expression of certain molecules postulated, based on preclinical models, to play a central role in the pathogenesis of IPF. Important findings include a pronounced and consistent elevation in ITAC/CXCL11 levels across the lung and plasma compartments, with trends toward downregulation of fibrotic and angiogenic molecules. We suggest that mortality in patients with IPF could potentially be altered by IFN- $\gamma$  1b through antimicrobial, antiangiogenic, antifibrotic, and/or immunomodulatory effects. Thus, our findings support the potential utility of IFN- $\gamma$  1b in the treatment of IPF.

**Conflict of Interest Statement:** R.M.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; K.M.S. is a study sponsor employee of InterMune and has patents pending and stock options; R.I.E. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript; I.N. received \$3,000 in 2003 and \$1,000 in 2002 for an advisory board and speaking engagement sponsored by InterMune; V.G.V. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.

**Acknowledgment:** The authors thank Ms. Farah Gowgani for outstanding study management, Dr. Dan Liberthson for editorial assistance, and Drs. Talmadge E. King, Jr., Fernando Martinez, Paul Noble, Ganesh Raghu, David Schwartz, and Mr. Jack Wanger for serving as study advisors. The authors also thank Dr. James Pennington for his helpful review of the manuscript and Mr. Philip Hormel for statistical advice.

## References

- International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. *N Engl J Med* 1991;324:509-516.
- Key LL Jr, Rodriguez RM, Willi SM, Wright NM, Hatcher HC, Eyre DR, Cure JK, Griffin PP, Ries WL. Long-term treatment of osteopetrosis with recombinant human interferon gamma. *N Engl J Med* 1995;332:1594-1599.
- Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, King TE Jr. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. *N Engl J Med* 2004;350:125-133.
- Lynch JP III, Toews GB. Idiopathic pulmonary fibrosis. In: Fishman A, editor. *Fishman's pulmonary diseases and disorders*, 3rd ed. New York: McGraw-Hill; 1998. p. 1069-1084.
- American Thoracic Society/European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med* 2002;165:277-304.
- American Thoracic Society/European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. *Am J Respir Crit Care Med* 2000;161:646-664.
- Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. *Am J Respir Crit Care Med* 1998;157:1301-1315.
- Keane MP, Arenberg DA, Lynch JP III, Whyte RI, Iannettoni MD, Burdick MD, Wilke CA, Morris SB, Glass MC, DiGiovine B, et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. *J Immunol* 1997;159:1437-1443.
- Renzone EA, Walsh DA, Salmon M, Wells AU, Sestini P, Nicholson AG, Veeraraghavan S, Bishop AE, Romanska HM, Pantelidis P, et al. Interstitial vascularity in fibrosing alveolitis. *Am J Respir Crit Care Med* 2003;167:438-443.
- Strieter RM, Belperio JA, Keane MP. CXC chemokines in angiogenesis related to pulmonary fibrosis. *Chest* 2002;122:298S-301S.
- Tang YW, Johnson JE, Browning PJ, Cruz-Gervis RA, Davis A, Graham BS, Brigham KL, Oates JA Jr, Loyd JE, Stecenko AA. Herpes virus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. *J Clin Microbiol* 2003;41:2633-2640.
- Keane MP, Henson PM, Strieter RM. Inflammation, injury, and repair. In: Murray JF, Nadel JA, Mason R, Boushey H, editors. *Textbook of respiratory medicine*, 3rd ed. Philadelphia: WB Saunders; 2000. p. 495-538.
- Keane MP, Belperio JA, Strieter RM. Cytokine biology and the pathogenesis of interstitial lung disease. In: Schwarz MI, King TE, editors. *Interstitial lung disease*, 4th ed. Hamilton, Ontario: B.C. Decker; 2003. p. 245-275.
- Narayanan AS, Whitley J, Souza A, Raghu G. Effect of gamma-interferon on collagen synthesis by normal and fibrotic human lung fibroblasts. *Chest* 1992;101:1326-1331.
- Rosenbloom J, Feldman G, Freundlich B, Jimenez SA. Transcriptional control of human diploid fibroblast collagen synthesis by gamma-interferon. *Biochem Biophys Res Commun* 1984;123:365-372.
- Okada T, Sugie I, Aisaka K. Effects of gamma-interferon on collagen and histamine content in bleomycin-induced lung fibrosis in rats. *Lymphokine Cytokine Res* 1993;12:87-91.
- Varga J, Olsen A, Herhal J, Constantine G, Rosenbloom J, Jimenez SA. Interferon-gamma reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-beta in normal human fibroblasts. *Eur J Clin Invest* 1990;20:487-493.
- Ji J, Si L, Fang W, Ling W. Interferon-gamma inhibits in situ expression of PDGF-beta mRNA by smooth muscle cells in injured rabbit arteries after transluminal balloon angioplasty. *Chin Med J* 2001;114:139-142.
- Schnyder-Candrian S, Strieter RM, Kunkel SL, Walz A. Interferon-alpha and interferon-gamma down-regulate the production of interleukin-8 and ENA-78 in human monocytes. *J Leukoc Biol* 1995;57:929-935.
- Wen FQ, Liu XD, Terasaki Y, Fang QH, Kobayashi T, Abe S, Rennard SI. Interferon-gamma reduces interleukin-4 and interleukin-13-augmented transforming growth factor-beta2 production in human bronchial epithelial cells by targeting SMADS. *Chest* 2003;123(Suppl 1):272S-273S.
- Cole AM, Ganz T, Liese AM, Burdick MD, Liu L, Strieter RM. Cutting edge: IFN-inducible ELR-CXC chemokines display defensin-like antimicrobial activity. *J Immunol* 2001;167:623-627.
- Strieter RM, Belperio JA, Phillips RJ, Dubinett SM, Keane MP. Chemokines in lung cancer. In: Strieter RM, Kunkel SL, Standiford TJ, edi-

- tors. Chemokines in the lung. New York: Marcel Dekker; 2003. p. 297–324.
23. Cole KE, Strick CA, Paradis TJ, Osborne KT, Loetscher M, Gladue RP, Lin W, Boyd JG, Moser B, Wood DE, *et al*. Interferon-inducible T cell alpha chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. *J Exp Med* 1998;187:2009–2021.
  24. Ulloa L, Doody J, Massague J. Inhibition of transforming growth factor-beta/SMAD signaling by the interferon-gamma/STAT pathway. *Nature* 1999;397:710–713.
  25. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. *N Engl J Med* 1999;341:1264–1269.
  26. Hyde DM, Henderson TS, Giri SN, Tyler NK, Stovall MY. Effect of murine gamma interferon on the cellular responses to bleomycin in mice. *Exp Lung Res* 1988;14:687–704.
  27. Hoff CR, Perkins DR, Davidson JM. Elastin gene expression is upregulated during pulmonary fibrosis. *Connect Tissue Res* 1999;40:145–153.
  28. Chettabi S, Ferguson MWJ. Wound repair. In: Gallin JI, Snyderman R, editors. Inflammation: basic principles and clinical correlates. Philadelphia: Lippincott, Williams, and Wilkins; 1999. p. 865–881.
  29. Nagaoka I, Trapnell BC, Crystal RG. Upregulation of platelet-derived growth factor-A and -B gene expression in alveolar macrophages of individuals with idiopathic pulmonary fibrosis. *J Clin Invest* 1990;85:2023–2027.
  30. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. *J Clin Invest* 1992;90:1479–1485.
  31. Postlethwaite AE, Seyer JM. Fibroblast chemotaxis induction by human recombinant interleukin-4: identification by synthetic peptide analysis of two chemotactic domains residing in amino acid sequences 70–88 and 89–122. *J Clin Invest* 1991;87:2147–2152.
  32. Schiff DE, Rae J, Martin TR, Davis BH, Curnutte JT. Increased phagocyte Fc gammaRI expression and improved Fc gamma-receptor-mediated phagocytosis after *in vivo* recombinant human interferon-gamma treatment of normal human subjects. *Blood* 1997;90:3187–3194.
  33. Romagnani P, Annunziato F, Lasagni L, Lazzeri E, Beltrame C, Francalanci M, Ugucioni M, Galli G, Cosmi L, Maurenzig L, *et al*. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. *J Clin Invest* 2001;107:53–63.
  34. Lasagni L, Francalanci M, Annunziato F, Lazzeri E, Giannini S, Cosmi L, Sagrinati C, Mazzinghi B, Orlando C, Maggi E, *et al*. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. *J Exp Med* 2003;197:1537–1549.
  35. Keane MP, Belperio JA, Arenberg DA, Burdick MD, Xu ZJ, Xue YY, Strieter RM. IFN-gamma-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. *J Immunol* 1999;163:5686–5692.
  36. Belperio JA, Keane MP, Arenberg DA, Addison CL, Ehlert JE, Burdick MD, Strieter RM. CXC chemokines in angiogenesis. *J Leukoc Biol* 2000;68:1–8.
  37. Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2001;164:2239–2242.